What Happened?

Congress is examining ways to strengthen U.S. generic-drug manufacturing as an estimated 70 percent to 80 percent of the active pharmaceutical ingredients used in U.S. medicines originate abroad. [](#ngr-597a7eb1-88fa-4732-aa7e-edae844f627d)

The Senate Special Committee on Aging scheduled a Sept. 23, hearing titled “Hearings To Examine Leveling The Playing Field, Focusing On Restoring America's Edge In Generic Drug Manufacturing.”

The U.S. Food and Drug Administration held a public meeting about generic-drug policy on Sept. 17.

Why Does it Matter to Me?

FDA programs offer priority review for certain generic-drug applications involving domestic manufacturing.

A proposal would provide faster facility inspections before a drug application is submitted.

The U.S. generic pharmaceutical manufacturing industry's market size declined at a compound annual growth rate of 7.8 percent between 2021 and 2026, while 461 generic pharmaceutical manufacturing businesses were listed in the United States in 2026.

Both Sides, Now

Congress is examining the policy question, while FDA programs already offer priority review for some generic-drug applications involving domestic manufacturing. The proposal would change the timing of facility inspections by allowing them to happen faster before a drug application is submitted. Hikma Pharmaceuticals USA Inc. addressed health and pharmaceutical policies, domestic pharmaceutical manufacturing supply-chain issues, drug shortages, and trade policies affecting domestic generic pharmaceutical manufacturing in lobbying filings covering the fourth quarter of 2025 through the second quarter of 2026. Legis1 reports that Hikma spent $130,000 on lobbying across that period, including $40,000 in the fourth quarter of 2025, $30,000 in the first quarter of 2026, and $60,000 in the second quarter of 2026.

What Happens Next?

Sen. Rick Scott is chair of the Senate Special Committee on Aging for the Sept. 23 hearing, and Sen. Kirsten Gillibrand is its ranking member.

The current GDUFA authorization expires in September 2027.

---

This article was generated by AI pulling from data. Each article is edited by an editor for accuracy and clarity.

---

Spot something wrong? Report an issue with this article